06:22:04 EDT Fri 12 Apr 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:INMB from 2023-04-13 to 2024-04-12 - 32 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-08 08:00U:INMBNews ReleaseINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
2024-03-28 16:02U:INMBNews ReleaseINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
2024-03-26 16:01U:INMBNews ReleaseINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
2024-03-13 08:00U:INMBNews ReleaseINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
2024-03-05 08:00U:INMBNews ReleaseINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro(TM)
2024-02-12 09:00U:INMBNews ReleaseINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-02-06 09:00U:INMBNews ReleaseINmune Bio to Participate in Baird ¢ € ™s Biotech Discovery Series Webcast on February 13, 2024
2024-01-30 08:00U:INMBNews ReleaseINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer ¢ € ™s Disease Program
2024-01-16 08:30U:INMBNews ReleaseELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
2024-01-02 08:00U:INMBNews ReleaseINmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune ¢ „ ¢ in Patients with Metastatic Castration-Resistant Prostate Cancer
2023-12-18 16:01U:INMBNews ReleaseINmune Bio Provides Update Regarding Global Alzheimer ¢ € ™s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
2023-11-29 08:00U:INMBNews ReleaseINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
2023-11-27 08:00U:INMBNews ReleaseINmune Bio Receives EMA ¢ € ™s Authorization in France and Spain for Phase II Clinical Trial of XPro ¢ „ ¢ for Early Alzheimer ¢ € ™s Disease
2023-11-15 09:00U:INMBNews ReleaseINmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer ¢ € ™s Disease in Europe
2023-11-01 16:11U:INMBNews ReleaseINmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
2023-10-31 08:00U:INMBNews ReleaseINmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune ¢ „ ¢ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
2023-10-30 09:07U:INMBNews ReleaseINmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRP Ž ±
2023-10-17 08:00U:INMBNews ReleaseINmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro ¢ „ ¢ to Treat Alzheimer ¢ € ™s Disease at Clinical Trials on Alzheimer ¢ € ™s Disease (CTAD) Conference
2023-10-16 09:00U:INMBNews ReleaseINmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
2023-09-07 09:00U:INMBNews ReleaseINmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
2023-09-05 08:00U:INMBNews ReleaseINmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer ¢ € ™s Disease
2023-08-07 16:00U:INMBNews ReleaseINmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
2023-08-01 08:00U:INMBNews ReleaseINmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
2023-07-31 08:00U:INMBNews ReleaseINmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
2023-07-12 08:00U:INMBNews ReleaseINmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
2023-07-11 08:00U:INMBNews ReleaseINmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer ¢ € ™s Disease
2023-07-10 16:00U:INMBNews ReleaseINmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro ¢ „ ¢ Promotes Remyelination by Affecting Astroglial and Microglial Biology
2023-05-24 09:00U:INMBNews ReleaseINmune Bio Inc. ¢ € ™s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
2023-05-08 08:00U:INMBNews ReleaseINmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune ¢ „ ¢, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
2023-05-03 16:11U:INMBNews ReleaseINmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update
2023-04-24 09:00U:INMBNews ReleaseINmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
2023-04-19 08:30U:INMBNews ReleaseXPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer ¢ € ™s Disease